Hunan Jinpu Pharmaceutical Technology Co., Ltd.

Primary objective: To investigate the bioequivalence of Lercanidipine Hydrochloride Tablets (20 mg) developed by Hunan Jinpu Pharmaceutical Technology Co., Ltd. and Lercanidipine Hydrochloride Tablets (20 mg; trade name: Zanidip®) produced by Recordati Industria Chimica e Farmaceutica S.p.A. in healthy Chinese subjects under fasting conditions. Secondary objective: To evaluate the safety of the test and reference formulations of Lercanidipine Hydrochloride Tablets in healthy subjects.

Primary objective: To evaluate the bioequivalence of the two preparations in the fasting and fed state in healthy Chinese subjects, using the aluminum magnesium aspirin tablets (II) (trade name: BUFFERIN Combination Tab. A81, specification: each tablet contains 81 mg aspirin, 22 mg heavy magnesium carbonate, 11 mg aluminum glycolate) from Lion Corporation as the reference preparation and the aluminum magnesium aspirin tablets (II) (specification: each tablet contains 81 mg aspirin, 22 mg heavy magnesium carbonate, 11 mg aluminum glycolate) developed by Hunan Jinpu Pharmaceutical Technology Co., Ltd. as the test preparation. Secondary objective: To evaluate the safety of the test preparation and the reference preparation in healthy Chinese subjects.

Main purpose: Using the flurbiprofen gel patch (containing 40 mg of flurbiprofen per patch (area 13.6 cm × 10.0 cm, containing 12 g of paste), trade name Zepolas®) of the licensed manufacturer MIKASA SEIYAKU CO., LTD as the reference preparation, and the flurbiprofen gel patch (containing 12 g of paste per patch (area 13.6 cm × 10.0 cm), containing 40 mg of flurbiprofen) developed by Hunan Jinpu Pharmaceutical Technology Co., Ltd. as the test preparation, the bioequivalence of the two preparations under topical conditions in Chinese healthy subjects was evaluated. Secondary objectives: 1) To evaluate the safety of the test preparation and the reference preparation in Chinese healthy subjects; 2) To evaluate the adhesion of the test preparation and the reference preparation during the medication process in Chinese healthy subjects; 3) To evaluate the skin reactivity of the test preparation and the reference preparation in Chinese healthy subjects.